Gsk (GLAXF) Receivables - Net (2016 - 2025)
Gsk has reported Receivables - Net over the past 10 years, most recently at $9.9 billion for Q4 2025.
- Quarterly results put Receivables - Net at $9.9 billion for Q4 2025, up 13.26% from a year ago — trailing twelve months through Dec 2025 was $9.9 billion (up 13.26% YoY), and the annual figure for FY2025 was $9.9 billion, up 13.26%.
- Receivables - Net for Q4 2025 was $9.9 billion at Gsk, up from $8.8 billion in the prior quarter.
- Over the last five years, Receivables - Net for GLAXF hit a ceiling of $10.6 billion in Q4 2021 and a floor of $8.3 billion in Q4 2022.
- Median Receivables - Net over the past 5 years was $9.2 billion (2023), compared with a mean of $9.3 billion.
- Biggest five-year swings in Receivables - Net: grew 15.42% in 2021 and later decreased 21.92% in 2022.
- Gsk's Receivables - Net stood at $10.6 billion in 2021, then fell by 21.92% to $8.3 billion in 2022, then increased by 10.8% to $9.2 billion in 2023, then fell by 4.28% to $8.8 billion in 2024, then grew by 13.26% to $9.9 billion in 2025.
- The last three reported values for Receivables - Net were $9.9 billion (Q4 2025), $8.8 billion (Q4 2024), and $9.2 billion (Q4 2023) per Business Quant data.